Compare Cart
  • Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Cover Image
Market Research Report
Product code 
1070547

Metabolomics Market by Product and Service, Application, and Indication : Global Opportunity Analysis and Industry Forecast, 2021--2030
Published: | Allied Market Research | 270 Pages | Delivery time: 2-3 business days

Price

Back to Top
Metabolomics Market by Product and Service, Application, and Indication : Global Opportunity Analysis and Industry Forecast, 2021--2030
Published: March 7, 2022
Allied Market Research
Content info: 270 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

Metabolomics is study and analysis of biochemical processes involving intermediates and products of metabolic activity. The products are called as metabolomes that reflect a cluster of all metabolites involved in a reaction within an organism which includes metabolic intermediates, signaling molecules, secondary metabolites, and hormones.

Metabolomics includes utilization of various analytical processes for determination of metabolites which include spectroscopy, chromatography, and multivariate analysis. Metabolites are closely related to the phenotype of an organism and can be used for wide range of applications such as substantial equivalence testing and phenotyping of genetically modified plants, identification of gene function, and biotic-abiotic stress reaction analysis. Furthermore, it also allows researchers and scientists to calculate physiological effects and observe the adverse reaction of drugs on an organism.

Increased adoption of metabolomics in precision medicine, continues technological advances in medical devices is expected to drive the metabolomics market. Moreover, increased private and government funding for metabolomics R&D is expected to propel the metabolomics market in the analysis period. However, the high cost of analytical and equipment and their maintenance, and lack of effective data management is expected to encumber the market growth.

The metabolomics market is segmented based on product & services, applications, indications, and geography. Based on product and service, it is divided into metabolomics instruments and metabolomics bioinformatics tools & services. Metabolomics instruments are further classified into separation tools (high-performance liquid chromatography, gas chromatography, ultra-performance liquid chromatography, and capillary electrophoresis) and detection technique (mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis). Metabolomics bioinformatics tools and services are further divided into bioinformatics tools & databases and bioinformatics services. Based on application, the market is categorized into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and other applications. Based on indications, it is divided into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and other indications.

By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Product development and research collaborations are the key strategies adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global metabolomics market.

  • The overall impact of COVID-19 on the metabolomics market was fairly positive. This was due to the fact that metabolomics was applied in research to study COVID-19 disease. For instance, metabolomics is used for analysis of volatile organic compounds exhaled by COVID-19 patients. Thus, this quality of metabolomics led to its applications in a large-scale screening of population in point-of-care (POC) setting. In addition, active research is also ongoing related to the discovery of potential metabolomics-based prognostic markers for COVID-19. Similarly, a number of metabolic pathways related to energy metabolism, amino acid, and lipids were found to be affected by severe disease with COVID-19.
  • Hence, the rise in demand of metabolomics products for COVID-19 related research lead to a surge in growth of market which in turn impacted the market in a positive manner. KEY BENEFITS FOR STAKEHOLDERS
  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the Metabolomics Market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

  • By Product and Service
    • Metabolomics Instruments
    • Separation Techniques
      • High Performance Liquid Chromatography
      • Gas Chromatography
      • Ultra Performance Liquid chromatography
      • Capillary Electrophoresis
    • Detection Technique
      • Mass Spectrometry
      • Nuclear Magnetic Resonance Spectrometry
      • Surface Based Mass Analysis
    • Metabolomics Bioinformatic Tools and services
    • Bioinformatic Services
    • Bioinformatics Tools and Database
  • By Application
    • Biomarkers Discovery
    • Drug Discovery
    • Nutrigenomics
    • Toxivology Testing
    • Functional Genomics
    • Personalized Medicine
    • Others
  • By Indication
    • Cancer
    • Cardiovascular Disease
    • Neurological Disorders
    • Inborn Errors of Metabolism
    • Other
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

KEY MARKET PLAYERS

  • #Agilent Technologies, Inc.
  • #Danaher Corporation
  • #Biocrates Life Sciences AG
  • Bruker Corporation
  • LECO Corporation
  • Metabolon, Inc.
  • Human Metabolome Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Shimadzu Corporation
  • Waters Corporation
Product Code: LI_17525 / A00423

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report Description
  • 1.2.Key Market Segments
  • 1.3.Key Benefits
  • 1.4.Research Methodology
    • 1.4.1.Primary Research
    • 1.4.2.Secondary Research
    • 1.4.3.Analyst Tools and Models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO Perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market Definition and Scope
  • 3.2.Key Findings
    • 3.2.1.Top Investment Pockets
    • 3.2.2.Top Winning Strategies
  • 3.3.Porter's Five Forces Analysis
    • 3.3.1.Bargaining Power of Suppliers
    • 3.3.2.Threat of New Entrants
    • 3.3.3.Threat of Substitutes
    • 3.3.4.Competitive Rivalry
    • 3.3.5.Bargaining Power among Buyers
  • 3.4.Market Share Analysis/Top Player Positioning
    • 3.4.1. Market Share Analysis/Top Player Positioning 2020
  • 3.5.Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities
  • 3.6.COVID-19 Impact Analysis

CHAPTER 4:METABOLOMICS MARKET, BY PRODUCT AND SERVICES

  • 4.1.Market Overview
  • 4.1.1Market Size and Forecast, By Product And Services
  • 4.2. Metabolomics Instruments
    • 4.2.1.Key Market Trends, Growth Factors and Opportunities
    • 4.2.2.Market Size and Forecast, By Region
    • 4.2.3.Market Share Analysis, By Country
    • 4.2.4.Separation Tools
      • 4.2.4.1.Market Size and Forecast
      • 4.2.5.2.High-Performance Liquid Chromatography
      • 4.2.5.2.1.Market Size and Forecast
      • 4.2.5.2.Gas Chromatography
      • 4.2.5.2.1.Market Size and Forecast
      • 4.2.5.2.Ultra Performance Liquid Chromatography
      • 4.2.5.2.1.Market Size and Forecast
      • 4.2.5.2.Capillary Electrophoresis
      • 4.2.5.2.1.Market Size and Forecast
    • 4.2.5.Detection Tools
      • 4.2.5.1.Market Size and Forecast
      • 4.2.6.2.Mass Spectrometry
      • 4.2.6.2.1.Market Size and Forecast
      • 4.2.6.2.Nuclear Magnetic Resonance Spectroscopy
      • 4.2.6.2.1.Market Size and Forecast
      • 4.2.6.2.Surface-Based Mass Analysis
      • 4.2.6.2.1.Market Size and Forecast
  • 4.3. Metabolomics Bioinformatics Tools And Services
    • 4.3.1.Key Market Trends, Growth Factors and Opportunities
    • 4.3.2.Market Size and Forecast, By Region
    • 4.3.3.Market Share Analysis, By Country
    • 4.3.4.Bioinformatics Tools
      • 4.3.4.1.Market Size and Forecast
    • 4.3.5.Databases and Bioinformatics Services
      • 4.3.5.1.Market Size and Forecast

CHAPTER 5:METABOLOMICS MARKET, BY APPLICATION

  • 5.1.Market Overview
  • 5.1.1Market Size and Forecast, By Application
  • 5.2. Biomarker Discovery
    • 5.2.1.Key Market Trends, Growth Factors and Opportunities
    • 5.2.2.Market Size and Forecast, By Region
    • 5.2.3.Market Share Analysis, By Country
  • 5.3. Drug Discovery
    • 5.3.1.Key Market Trends, Growth Factors and Opportunities
    • 5.3.2.Market Size and Forecast, By Region
    • 5.3.3.Market Share Analysis, By Country
  • 5.4. Toxicology Testing
    • 5.4.1.Key Market Trends, Growth Factors and Opportunities
    • 5.4.2.Market Size and Forecast, By Region
    • 5.4.3.Market Share Analysis, By Country
  • 5.5. Nutrigenomics
    • 5.5.1.Key Market Trends, Growth Factors and Opportunities
    • 5.5.2.Market Size and Forecast, By Region
    • 5.5.3.Market Share Analysis, By Country
  • 5.6. Functional Genomics
    • 5.6.1.Key Market Trends, Growth Factors and Opportunities
    • 5.6.2.Market Size and Forecast, By Region
    • 5.6.3.Market Share Analysis, By Country
  • 5.7. Personalized Medicine
    • 5.7.1.Key Market Trends, Growth Factors and Opportunities
    • 5.7.2.Market Size and Forecast, By Region
    • 5.7.3.Market Share Analysis, By Country
  • 5.8. Other Applications
    • 5.8.1.Key Market Trends, Growth Factors and Opportunities
    • 5.8.2.Market Size and Forecast, By Region
    • 5.8.3.Market Share Analysis, By Country

CHAPTER 6:METABOLOMICS MARKET, BY INDICATION

  • 6.1.Market Overview
  • 6.1.1Market Size and Forecast, By Indication
  • 6.2. Cancer
    • 6.2.1.Key Market Trends, Growth Factors and Opportunities
    • 6.2.2.Market Size and Forecast, By Region
    • 6.2.3.Market Share Analysis, By Country
  • 6.3. Cardiovascular Disorders
    • 6.3.1.Key Market Trends, Growth Factors and Opportunities
    • 6.3.2.Market Size and Forecast, By Region
    • 6.3.3.Market Share Analysis, By Country
  • 6.4. Neurological Disorders
    • 6.4.1.Key Market Trends, Growth Factors and Opportunities
    • 6.4.2.Market Size and Forecast, By Region
    • 6.4.3.Market Share Analysis, By Country
  • 6.5. Inborn Errors Of Metabolism
    • 6.5.1.Key Market Trends, Growth Factors and Opportunities
    • 6.5.2.Market Size and Forecast, By Region
    • 6.5.3.Market Share Analysis, By Country
  • 6.6. Other Indications
    • 6.6.1.Key Market Trends, Growth Factors and Opportunities
    • 6.6.2.Market Size and Forecast, By Region
    • 6.6.3.Market Share Analysis, By Country

CHAPTER 7:METABOLOMICS MARKET, BY REGION

  • 7.1.Market Overview
  • 7.1.1Market Size and Forecast, By Region
  • 7.2.North America
    • 7.2.1.Key Market Trends and Opportunities
    • 7.2.2.Market Size and Forecast, By Product And Services
    • 7.2.3.Market Size and Forecast, By Application
    • 7.2.4.Market Size and Forecast, By Indication
    • 7.2.5.Market Size and Forecast, By Country
    • 7.2.6.United States Metabolomics Market
      • 7.2.6.1.Market Size and Forecast, By Product And Services
      • 7.2.6.2.Market Size and Forecast, By Application
      • 7.2.6.3.Market Size and Forecast, By Indication
    • 7.2.7.Canada Metabolomics Market
      • 7.2.7.1.Market Size and Forecast, By Product And Services
      • 7.2.7.2.Market Size and Forecast, By Application
      • 7.2.7.3.Market Size and Forecast, By Indication
    • 7.2.8.Mexico Metabolomics Market
      • 7.2.8.1.Market Size and Forecast, By Product And Services
      • 7.2.8.2.Market Size and Forecast, By Application
      • 7.2.8.3.Market Size and Forecast, By Indication
  • 7.3.Europe
    • 7.3.1.Key Market Trends and Opportunities
    • 7.3.2.Market Size and Forecast, By Product And Services
    • 7.3.3.Market Size and Forecast, By Application
    • 7.3.4.Market Size and Forecast, By Indication
    • 7.3.5.Market Size and Forecast, By Country
    • 7.3.6.Germany Metabolomics Market
      • 7.3.6.1.Market Size and Forecast, By Product And Services
      • 7.3.6.2.Market Size and Forecast, By Application
      • 7.3.6.3.Market Size and Forecast, By Indication
    • 7.3.7.France Metabolomics Market
      • 7.3.7.1.Market Size and Forecast, By Product And Services
      • 7.3.7.2.Market Size and Forecast, By Application
      • 7.3.7.3.Market Size and Forecast, By Indication
    • 7.3.8.Uk Metabolomics Market
      • 7.3.8.1.Market Size and Forecast, By Product And Services
      • 7.3.8.2.Market Size and Forecast, By Application
      • 7.3.8.3.Market Size and Forecast, By Indication
    • 7.3.9.Italy Metabolomics Market
      • 7.3.9.1.Market Size and Forecast, By Product And Services
      • 7.3.9.2.Market Size and Forecast, By Application
      • 7.3.9.3.Market Size and Forecast, By Indication
    • 7.3.10.Spain Metabolomics Market
      • 7.3.10.1.Market Size and Forecast, By Product And Services
      • 7.3.10.2.Market Size and Forecast, By Application
      • 7.3.10.3.Market Size and Forecast, By Indication
    • 7.3.11.Rest Of Europe Metabolomics Market
      • 7.3.11.1.Market Size and Forecast, By Product And Services
      • 7.3.11.2.Market Size and Forecast, By Application
      • 7.3.11.3.Market Size and Forecast, By Indication
  • 7.4.Asia-Pacific
    • 7.4.1.Key Market Trends and Opportunities
    • 7.4.2.Market Size and Forecast, By Product And Services
    • 7.4.3.Market Size and Forecast, By Application
    • 7.4.4.Market Size and Forecast, By Indication
    • 7.4.5.Market Size and Forecast, By Country
    • 7.4.6.Japan Metabolomics Market
      • 7.4.6.1.Market Size and Forecast, By Product And Services
      • 7.4.6.2.Market Size and Forecast, By Application
      • 7.4.6.3.Market Size and Forecast, By Indication
    • 7.4.7.China Metabolomics Market
      • 7.4.7.1.Market Size and Forecast, By Product And Services
      • 7.4.7.2.Market Size and Forecast, By Application
      • 7.4.7.3.Market Size and Forecast, By Indication
    • 7.4.8.Australia Metabolomics Market
      • 7.4.8.1.Market Size and Forecast, By Product And Services
      • 7.4.8.2.Market Size and Forecast, By Application
      • 7.4.8.3.Market Size and Forecast, By Indication
    • 7.4.9.India Metabolomics Market
      • 7.4.9.1.Market Size and Forecast, By Product And Services
      • 7.4.9.2.Market Size and Forecast, By Application
      • 7.4.9.3.Market Size and Forecast, By Indication
    • 7.4.10.South Korea Metabolomics Market
      • 7.4.10.1.Market Size and Forecast, By Product And Services
      • 7.4.10.2.Market Size and Forecast, By Application
      • 7.4.10.3.Market Size and Forecast, By Indication
    • 7.4.11.Rest Of Asia-pacific Metabolomics Market
      • 7.4.11.1.Market Size and Forecast, By Product And Services
      • 7.4.11.2.Market Size and Forecast, By Application
      • 7.4.11.3.Market Size and Forecast, By Indication
  • 7.5.LAMEA
    • 7.5.1.Key Market Trends and Opportunities
    • 7.5.2.Market Size and Forecast, By Product And Services
    • 7.5.3.Market Size and Forecast, By Application
    • 7.5.4.Market Size and Forecast, By Indication
    • 7.5.5.Market Size and Forecast, By Country
    • 7.5.6.Brazil Metabolomics Market
      • 7.5.6.1.Market Size and Forecast, By Product And Services
      • 7.5.6.2.Market Size and Forecast, By Application
      • 7.5.6.3.Market Size and Forecast, By Indication
    • 7.5.7.Saudi Arabia Metabolomics Market
      • 7.5.7.1.Market Size and Forecast, By Product And Services
      • 7.5.7.2.Market Size and Forecast, By Application
      • 7.5.7.3.Market Size and Forecast, By Indication
    • 7.5.8.South Africa Metabolomics Market
      • 7.5.8.1.Market Size and Forecast, By Product And Services
      • 7.5.8.2.Market Size and Forecast, By Application
      • 7.5.8.3.Market Size and Forecast, By Indication
    • 7.5.9.Rest of LAMEA Metabolomics Market
      • 7.5.9.1.Market Size and Forecast, By Product And Services
      • 7.5.9.2.Market Size and Forecast, By Application
      • 7.5.9.3.Market Size and Forecast, By Indication

CHAPTER 8:COMPANY PROFILES

  • 8.1. Agilent Technologies, Inc.
    • 8.1.1.Company Overview
    • 8.1.2.Key Executives
    • 8.1.3.Company snapshot
    • 8.1.4.Operating business segments
    • 8.1.5.Product portfolio
    • 8.1.6.Business Performance
    • 8.1.7.Key Strategic Moves and Developments
  • 8.2. Danaher Corporation
    • 8.2.1.Company Overview
    • 8.2.2.Key Executives
    • 8.2.3.Company snapshot
    • 8.2.4.Operating business segments
    • 8.2.5.Product portfolio
    • 8.2.6.Business Performance
    • 8.2.7.Key Strategic Moves and Developments
  • 8.3. Biocrates Life Sciences AG
    • 8.3.1.Company Overview
    • 8.3.2.Key Executives
    • 8.3.3.Company snapshot
    • 8.3.4.Operating business segments
    • 8.3.5.Product portfolio
    • 8.3.6.Business Performance
    • 8.3.7.Key Strategic Moves and Developments
  • 8.4. Bruker Corporation
    • 8.4.1.Company Overview
    • 8.4.2.Key Executives
    • 8.4.3.Company snapshot
    • 8.4.4.Operating business segments
    • 8.4.5.Product portfolio
    • 8.4.6.Business Performance
    • 8.4.7.Key Strategic Moves and Developments
  • 8.5. LECO Corporation
    • 8.5.1.Company Overview
    • 8.5.2.Key Executives
    • 8.5.3.Company snapshot
    • 8.5.4.Operating business segments
    • 8.5.5.Product portfolio
    • 8.5.6.Business Performance
    • 8.5.7.Key Strategic Moves and Developments
  • 8.6. Metabolon, Inc.
    • 8.6.1.Company Overview
    • 8.6.2.Key Executives
    • 8.6.3.Company snapshot
    • 8.6.4.Operating business segments
    • 8.6.5.Product portfolio
    • 8.6.6.Business Performance
    • 8.6.7.Key Strategic Moves and Developments
  • 8.7. Human Metabolome Technologies, Inc.
    • 8.7.1.Company Overview
    • 8.7.2.Key Executives
    • 8.7.3.Company snapshot
    • 8.7.4.Operating business segments
    • 8.7.5.Product portfolio
    • 8.7.6.Business Performance
    • 8.7.7.Key Strategic Moves and Developments
  • 8.8. Bio-Rad Laboratories, Inc.
    • 8.8.1.Company Overview
    • 8.8.2.Key Executives
    • 8.8.3.Company snapshot
    • 8.8.4.Operating business segments
    • 8.8.5.Product portfolio
    • 8.8.6.Business Performance
    • 8.8.7.Key Strategic Moves and Developments
  • 8.9. Shimadzu Corporation
    • 8.9.1.Company Overview
    • 8.9.2.Key Executives
    • 8.9.3.Company snapshot
    • 8.9.4.Operating business segments
    • 8.9.5.Product portfolio
    • 8.9.6.Business Performance
    • 8.9.7.Key Strategic Moves and Developments
  • 8.10. Waters Corporation
    • 8.10.1.Company Overview
    • 8.10.2.Key Executives
    • 8.10.3.Company snapshot
    • 8.10.4.Operating business segments
    • 8.10.5.Product portfolio
    • 8.10.6.Business Performance
    • 8.10.7.Key Strategic Moves and Developments

LIST OF TABLES

  • TABLE 1.GLOBAL METABOLOMICS MARKET, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 2.GLOBAL METABOLOMICS MARKET FOR METABOLOMICS INSTRUMENTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 3.GLOBAL METABOLOMICS MARKET FOR METABOLOMICS BIOINFORMATICS TOOLS AND SERVICES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 4.GLOBAL METABOLOMICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 5.GLOBAL METABOLOMICS MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 6.GLOBAL METABOLOMICS MARKET FOR DRUG DISCOVERY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 7.GLOBAL METABOLOMICS MARKET FOR TOXICOLOGY TESTING, BY REGION, 2020-2030 ($MILLION)
  • TABLE 8.GLOBAL METABOLOMICS MARKET FOR NUTRIGENOMICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 9.GLOBAL METABOLOMICS MARKET FOR FUNCTIONAL GENOMICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.GLOBAL METABOLOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.GLOBAL METABOLOMICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.GLOBAL METABOLOMICS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 13.GLOBAL METABOLOMICS MARKET FOR CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.GLOBAL METABOLOMICS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.GLOBAL METABOLOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.GLOBAL METABOLOMICS MARKET FOR INBORN ERRORS OF METABOLISM, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.GLOBAL METABOLOMICS MARKET FOR OTHER INDICATIONS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.GLOBAL METABOLOMICS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.NORTH AMERICA METABOLOMICS, BY Region, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 21.NORTH AMERICA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 22.NORTH AMERICA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 23.UNITED STATES METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 24.UNITED STATES METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 25.UNITED STATES METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 26.CANADA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 27.CANADA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 28.CANADA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 29.MEXICO METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 30.MEXICO METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 31.MEXICO METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 32.EUROPE METABOLOMICS, BY Region, 2020-2030 ($MILLION)
  • TABLE 33.EUROPE METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 34.EUROPE METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 35.EUROPE METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 36.GERMANY METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 37.GERMANY METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 38.GERMANY METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 39.FRANCE METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 40.FRANCE METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 41.FRANCE METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 42.UK METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 43.UK METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 44.UK METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 45.ITALY METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 46.ITALY METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 47.ITALY METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 48.SPAIN METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 49.SPAIN METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 50.SPAIN METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 51.REST OF EUROPE METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 52.REST OF EUROPE METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 53.REST OF EUROPE METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 54.ASIA-PACIFIC METABOLOMICS, BY Region, 2020-2030 ($MILLION)
  • TABLE 55.ASIA-PACIFIC METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 56.ASIA-PACIFIC METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 57.ASIA-PACIFIC METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 58.JAPAN METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 59.JAPAN METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 60.JAPAN METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 61.CHINA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 62.CHINA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 63.CHINA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 64.AUSTRALIA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 65.AUSTRALIA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 66.AUSTRALIA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 67.INDIA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 68.INDIA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 69.INDIA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 70.SOUTH KOREA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 71.SOUTH KOREA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 72.SOUTH KOREA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 76.LAMEA METABOLOMICS, BY Region, 2020-2030 ($MILLION)
  • TABLE 77.LAMEA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 78.LAMEA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 79.LAMEA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 80.BRAZIL METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 81.BRAZIL METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 82.BRAZIL METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 83.SAUDI ARABIA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 84.SAUDI ARABIA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 85.SAUDI ARABIA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 86.SOUTH AFRICA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 87.SOUTH AFRICA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 88.SOUTH AFRICA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 89.REST OF LAMEA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
  • TABLE 90.REST OF LAMEA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 91.REST OF LAMEA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 92.AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 93.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 94.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 95.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 96.AGILENT TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97.DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 98.DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 99.DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 100.DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 101.DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102.BIOCRATES LIFE SCIENCES AG: KEY EXECUTIVES
  • TABLE 103.BIOCRATES LIFE SCIENCES AG: COMPANY SNAPSHOT
  • TABLE 104.BIOCRATES LIFE SCIENCES AG: OPERATING SEGMENTS
  • TABLE 105.BIOCRATES LIFE SCIENCES AG: PRODUCT PORTFOLIO
  • TABLE 106.BIOCRATES LIFE SCIENCES AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107.BRUKER CORPORATION: KEY EXECUTIVES
  • TABLE 108.BRUKER CORPORATION: COMPANY SNAPSHOT
  • TABLE 109.BRUKER CORPORATION: OPERATING SEGMENTS
  • TABLE 110.BRUKER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 111.BRUKER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112.LECO CORPORATION: KEY EXECUTIVES
  • TABLE 113.LECO CORPORATION: COMPANY SNAPSHOT
  • TABLE 114.LECO CORPORATION: OPERATING SEGMENTS
  • TABLE 115.LECO CORPORATION: PRODUCT PORTFOLIO
  • TABLE 116.LECO CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117.METABOLON, INC.: KEY EXECUTIVES
  • TABLE 118.METABOLON, INC.: COMPANY SNAPSHOT
  • TABLE 119.METABOLON, INC.: OPERATING SEGMENTS
  • TABLE 120.METABOLON, INC.: PRODUCT PORTFOLIO
  • TABLE 121.METABOLON, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122.HUMAN METABOLOME TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 123.HUMAN METABOLOME TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 124.HUMAN METABOLOME TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 125.HUMAN METABOLOME TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 126.HUMAN METABOLOME TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127.BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 128.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 129.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 130.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 131.BIO-RAD LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132.SHIMADZU CORPORATION: KEY EXECUTIVES
  • TABLE 133.SHIMADZU CORPORATION: COMPANY SNAPSHOT
  • TABLE 134.SHIMADZU CORPORATION: OPERATING SEGMENTS
  • TABLE 135.SHIMADZU CORPORATION: PRODUCT PORTFOLIO
  • TABLE 136.SHIMADZU CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137.WATERS CORPORATION: KEY EXECUTIVES
  • TABLE 138.WATERS CORPORATION: COMPANY SNAPSHOT
  • TABLE 139.WATERS CORPORATION: OPERATING SEGMENTS
  • TABLE 140.WATERS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 141.WATERS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1.GLOBAL METABOLOMICS MARKET SEGMENTATION
  • FIGURE 2.GLOBAL METABOLOMICS MARKET
  • FIGURE 3.SEGMENTATION METABOLOMICS MARKET
  • FIGURE 4.TOP INVESTMENT POCKET IN METABOLOMICS MARKET
  • FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
  • FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
  • FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
  • FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 11.LOW THREAT OF SUBSTITUTION
  • FIGURE 12.HIGH COMPETITIVE RIVALRY
  • FIGURE 13.TOP PLAYER POSITIONING, 2020
  • FIGURE 14.MARKET SHARE ANALYSIS, 2020
  • FIGURE 15.RESTRAINTS AND DRIVERS: METABOLOMICS MARKET
  • FIGURE 16.METABOLOMICS MARKET SEGMENTATION, BY PRODUCT AND SERVICES
  • FIGURE 17.METABOLOMICS MARKET FOR METABOLOMICS INSTRUMENTS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 18.METABOLOMICS MARKET FOR METABOLOMICS BIOINFORMATICS TOOLS AND SERVICES, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 19.METABOLOMICS MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 20.METABOLOMICS MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 21.METABOLOMICS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 22.METABOLOMICS MARKET FOR TOXICOLOGY TESTING, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 23.METABOLOMICS MARKET FOR NUTRIGENOMICS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 24.METABOLOMICS MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 25.METABOLOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 26.METABOLOMICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 27.METABOLOMICS MARKET SEGMENTATION, BY INDICATION
  • FIGURE 28.METABOLOMICS MARKET FOR CANCER, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 29.METABOLOMICS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 30.METABOLOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 31.METABOLOMICS MARKET FOR INBORN ERRORS OF METABOLISM, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 32.METABOLOMICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 33.AGILENT TECHNOLOGIES, INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 35.AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 36.DANAHER CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 37.DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 38.DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 39.BIOCRATES LIFE SCIENCES AG: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.BIOCRATES LIFE SCIENCES AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 41.BIOCRATES LIFE SCIENCES AG: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 42.BRUKER CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.BRUKER CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 44.BRUKER CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 45.LECO CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 46.LECO CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 47.LECO CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 48.METABOLON, INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 49.METABOLON, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 50.METABOLON, INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 51.HUMAN METABOLOME TECHNOLOGIES, INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 52.HUMAN METABOLOME TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 53.HUMAN METABOLOME TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 54.BIO-RAD LABORATORIES, INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 55.BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 56.BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 57.SHIMADZU CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 58.SHIMADZU CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 59.SHIMADZU CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 60.WATERS CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 61.WATERS CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 62.WATERS CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)